Vera Therapeutics, Inc. (VERA) News
Track canonical SquawkNews coverage tagged to VERA, Vera Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Kura Sushi Posts Weak Q3 Sales, Joins FuelCell Energy And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Wednesday. Shares of Kura Sushi USA, Inc. (NASDAQ: KRUS ) fell sharply in pre-market trading after the company reported wor
EARNINGS | Jul 08, 2026, 12:04 PM UTC
L
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
H.C. Wainwright raised the firm's price target on Vera Therapeutics to $125 from $110 and keeps a Buy rating on the shares after the FDA granted accelerated approval to Trutakna with "a broad and clean label" to reduce p
REGULATION | Jul 08, 2026, 10:28 AM UTC
L
Vera Therapeutics price target raised to $70 from $65 at BofA
BofA raised the firm's price target on Vera Therapeutics to $70 from $65 and keeps a Buy rating on the shares following Trutakna's conditional FDA approval for the treatment of immunoglobulin A nephropathy. Trutakna's Ig
REGULATION | Jul 07, 2026, 06:09 PM UTC
L
Vera's Trutakna approved by FDA for adults with primary IgA nephropathy
The U.S. Food and Drug Administration has approved Trutakna to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Trutakna is injected subcutaneously once weekly. The
EQUITY | Jul 07, 2026, 04:29 PM UTC